By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Vancouver  British Columbia    Canada
Phone: n/a Fax: n/a


CEO: Mary Szela

Key Statistics

Ownership: Public

Web Site: Novelion
Symbol: AEGR

Company News
Novelion (AEGR)’ Request To Voluntarily Delist From The Toronto Stock Exchange Granted 4/20/2017 10:22:57 AM
Novelion (AEGR) Release: Metreleptin And Lipodystrophy Data Presented At The Annual Meeting Of The Endocrine Society 4/5/2017 11:34:41 AM
Novelion (AEGR) Appoints Mark Corrigan, M.D. To Board Of Directors 3/31/2017 9:46:00 AM
Novelion (AEGR) Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results 3/15/2017 8:36:27 AM
Novelion (AEGR) To Announce Preliminary Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017 3/14/2017 10:53:36 AM
Novelion (AEGR) Release: U.S. Patent Trial And Appeal Board Affirms Lomitapide Patents With Favorable IPR Decisions 3/7/2017 8:45:40 AM
Novelion (AEGR) Release: Biotech Announces Acceptance Of Marketing Authorization Application For Metreleptin By EMA 1/23/2017 6:52:24 AM
Novelion (AEGR) Reports Preliminary 2016 Net Product Sales And Provides 2017 Outlook 1/9/2017 7:43:35 AM
Novelion (AEGR)’s Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy 12/22/2016 8:28:44 AM
Novelion (AEGR) Completes Reverse Stock Split 12/19/2016 11:11:38 AM